A Study of Encorafenib Plus Cetuximab with or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Trial overview


Metastatic colorectal cancer


The purpose of the study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of-care chemotherapy in participants with previously untreated BRAF V600E-mutant mCRC. Since encorafenib has not previously been combined with chemotherapy, the tolerability and PK of EC in combination with mFOLFOX6 and in combination with FOLFIRI will be evaluated in separate cohorts in the safety lead-in portion of the trial in order to identify which chemotherapy combination is to be used in the Phase 3 portion of the study.

Eligibility criteria


  • Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation
  • Participants who have received ≤1 (Safety Lead-In) or no (Phase 3) prior systemic regimens for metastatic disease. 
  • Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment
  • Measurable disease (Phase 3)/ Measurable or non-measurable evaluable disease (Safety Lead-in)
  • ECOG PS 0-1
  • Adequate organ function

Key Exclusion Criteria:

  • Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition
  • Active bacterial or viral infections in 2 weeks prior to starting dosing
  • Symptomatic brain metastases


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.